Actively Recruiting
Using Blood Tests and Artificial Intelligence to Tell Benign From Malignant Lung Nodules Based on CT Imaging of Different Nodule Types
Led by China-Japan Friendship Hospital · Updated on 2024-12-18
150
Participants Needed
1
Research Sites
25 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating a new way to tell the difference between benign non-cancerous and malignant cancerous pulmonary nodules smaller than 3 cm in patients. This observational trial is focused on combining blood metabolomic analysis using mass spectrometry with artificial intelligence AI image analysis. The goal is to improve how accurately these nodules are identified as benign or malignant, which is important for patient diagnosis and treatment planning. Participants will be grouped based on the type of lung nodule seen on CT scans pure ground-glass nodules, part-solid nodules, or solid nodules. Each participant will provide a small sample of peripheral blood 4 mL for metabolomic testing. Machine learning algorithms will then analyze this data along with AI image analysis to build classification models for each nodule type. During the study, participants will undergo CT imaging and provide blood samples. Researchers will use mass spectrometry to characterize metabolites in the blood and apply machine learning to develop models that differentiate benign from malignant nodules. The main outcome is to establish a reliable model within 6 months. Participants must meet health criteria and provide informed consent. The study is sponsored by China-Japan Friendship Hospital and will continue until July 2025.
CONDITIONS
Brief Title
New Method to Differentiate Benign and Malignant Pulmonary Nodules.
Research Team
G
Guangying Zhu, doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here